Miguel Gómez Álvarez and Carlos Vallejo/X
Jun 12, 2026, 16:12
Miguel Gómez Álvarez: The Evidence on Disease Burden in PNH
Miguel Gómez Álvarez, Hematologist at Department of Hematology and Hemotherapy, Hospital Clínico San Carlos, Madrid, Spain, shared a post on X:
“Carlos Vallejo presents the evidence on the disease burden in PNH:
The importance of fatigue in patients already treated with iC5, the impact on quality of life, and the relevance of shared decision-making.”
Stay updated with Hemostasis Today.
-
Jun 12, 2026, 16:14Chokri Ben Lamine: EHA26 – SCD Curative Therapy Pathway
-
Jun 12, 2026, 16:13Talha Badar: Excellent Talk by Francesca Palandri on ET and PV at EHA 2026
-
Jun 12, 2026, 16:11Shinya Goto: The Japanese Investigators Behind Tranexamic Acid
-
Jun 12, 2026, 16:10Rahul Kumar: Improved Chemotherapy Delivery Is Meaningful Only When It Improves Patient Outcomes
-
Jun 12, 2026, 15:24A Practical Guide to Living Well with ITP – ITP Support Association
-
Jun 12, 2026, 15:16Courtney Lawrence: The AABB Bulletin on Neonatal Red Blood Cell Transfusion and Mannitol Exposure is Now Released
-
Jun 12, 2026, 15:05Sukanto Paul: Therapeutic Plasma Exchange as an Extracorporeal Liver Support Therapy
-
Jun 12, 2026, 14:40Daniel Auclair: Hematocure Team Shines at EHA 2026
-
Jun 12, 2026, 14:27Aoife Brennan: Ongoing Budo Study Demonstrates Potential in Challenging ITP Population